HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China
Yahoo Finance · Aug 31, 2026 · HCM (HCM)
Findings build on the established success of the global SAFFRON and China SACHI trials, extending the clinical value of the all-oral combination into the first-line settingHONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED“) (Nasdaq/AIM: HCM; HKEX: 13) today announces positive high-level results from the SANOVO China Phase III trial in treatment-naïve patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”
Not investment advice. Cached headline, not a full reprint.